Azafaros
Leiden
About Azafaros
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $175.1M
- Funding stage: Early Stage Venture
- Last round: Series B (May 2025)
- Website: azafaros.com
- Phone: +31 0 35 699 30 00
Industries & Categories
Biotechnology, Health Care, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/azafaros-115200 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.